Acyclovir News and Research RSS Feed - Acyclovir News and Research

Acyclovir is a synthetic analog of the purine nucleoside, guanosine, with potent antiviral activity against herpes simplex viruses type 1 and 2, varicella-zoster virus and other viruses. After conversion in vivo to the active metabolite acyclovir triphosphate, acyclovir competitively inhibits viral DNA polymerase, incorporates into and terminates the growing viral DNA chain, and inactivates viral DNA polymerase. The greater antiviral activity of acyclovir against HSV compared to VZV is due to its more efficient phosphorylation by the thymidine kinase of HSV.

Swedish agency approves Medivir's Xerclear for treatment of cold sores

21. December 2009 08:00
The Swedish Medical Products Agency has now approved Xerclear™ for treatment of cold sores. It is the first and only topical treatment that has been demonstrated to prevent the incidence of cold sores and shorten healing-times. Xerclear™ will be available from pharmacies in the first half-year 2010. [More]

BioAlliance Pharma SA to enter Phase II clinical trial for clonidine Lauriad and Phase I clinical trial for AMEP

15. December 2009 23:38
BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announces the approval from the French Drug Agency (AFFSSaPS) to enter Phase II clinical trial for clonidine Lauriad® in radiotherapy and chemotherapy-induced oral mucositis and the approval from Danish and Slovene Agencies to enter Phase I clinical trial for AMEPTM in invasive melanoma. [More]

Positive results from BioAlliance Pharma's acyclovir Lauriad phase III trial

10. December 2009 23:53
BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announces final positive results of its pivotal phase III clinical study in immunocompetent patients with recurrent herpes labialis (LIP Study) treated with acyclovir Lauriad®. Primary and secondary endpoints have been met with marked efficacy and good tolerance. [More]

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , ,

Phase I clinical trial results for Fentanyl Lauriad announced by BioAlliance Pharma

12. October 2009 03:24
BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the approval from the French Drug Agency (AFSSaPS) to enter first Phase I clinical trial for Fentanyl Lauriad®. [More]

Posted in: Drug Trial News

Tags: , , , , ,

FDA approves Sirion's Zirgan for treating acute herpetic keratitis

17. September 2009 01:46
Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) has approved its New Drug Application for Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% as a treatment for acute herpetic keratitis (dendritic ulcers). The FDA granted orphan drug designation to Zirgan for this indication in April 2007. [More]

Clinical trial data of Lipsovir presented at ICAAC

16. September 2009 02:46
Medivir presented Lipsovir (ME-609) at a poster session on 14th September at the ongoing ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy) meeting. [More]

Posted in: Pharmaceutical News

Tags: , , , , ,

BioAlliance Pharma posts revenue of €4.1 million for the first half of 2009

27. August 2009 01:33
BioAlliance Pharma SA (Paris:BIO) (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today presented its consolidated half-year accounts to June 30, 2009. [More]

BioAlliance Pharma's LIP phase III pivotal study provides positive preliminary results

27. August 2009 00:30
BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, is pleased today to announce positive preliminary results in its LIP phase III pivotal study (Lauriad® Immunocompetent Patients Study ). This multicenter randomized, double-blind, placebo controlled study compared the efficacy and safety of a single dose acyclovir Lauriad® 50mg Mucoadhesive Buccal Tablet (MBT) versus matching placebo in patients suffering from recurrent oro-facial herpes. [More]

Posted in: Drug Trial News

Tags: , , , ,

Nanoviricides anti-herpes drug candidate reduces viral load by 99.99%

10. August 2009 07:43
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), has announced that the herpes simplex viral load was reduced by 99.99% or 10,000 fold in in-vitro studies by nanoviricides™ drug candidates. [More]

US FDA approves Lipsovir for cold sores

3. August 2009 05:12
The US Food and Drug Administration (FDA) has now approved Lipsovir, i.e. granted Medivir's New Drug Application (NDA) for the use of acyclovir and hydrocortisone for early treatment of recurrent cold sores to decreases the risk of cold sores, and to shorten the healing time for those cold sores which are not prevented. [More]

Herpes drug Acyclovir does not reduce risk of HIV transmission, does slow HIV progression, study says

14. May 2009 20:02
The drug acyclovir, which suppresses herpes simplex virus-2, does not reduce the risk of HIV transmission when taken by HIV-positive people who also have herpes, according to a study conducted by researchers at the University of Washington, United Press International reports. [More]

Posted in: Drug Trial News

Tags: , , , , , ,

Anti-herpes drug acyclovir inhibits HIV replication, but with a price

7. November 2008 03:39
The anti-herpes drug acyclovir can also directly slow down HIV infection by targeting the reverse transcriptase (RT) enzyme, researchers report in this week's JBC. [More]

Posted in: Medical Research News

Tags: , , ,

Herpes drug Acyclovir could help control HIV

15. September 2008 04:58
Acyclovir -- a low-cost, generic drug used to treat herpes -- also might help control HIV in people living with both viruses, according to a study published Wednesday in the journal ell Host and Microbe, Reuters reports. [More]

Posted in: Disease/Infection News

Tags: , , , , , , ,

Herpes virus changes anti-herpes drug acyclovir to form that hinders AIDS virus

10. September 2008 19:54
The drug acyclovir has long been used to suppress outbreaks of oral and genital herpes. Herpes viruses change acyclovir to a form that prevents them from reproducing. [More]

Posted in: Medical Research News

Tags: , , , , , , , ,

New understanding of how herpes simplex virus 1 hides during inactive phase

3. July 2008 01:56
Now that Duke University Medical Center scientists have figured out how the virus that causes cold sores hides out, they may have a way to wake it up and kill it. [More]

Posted in: Medical Research News

Tags: , , , , , , , ,

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.